Alimera Sciences, Inc. (NASDAQ:ALIM) Sees Significant Increase in Short Interest

Alimera Sciences, Inc. (NASDAQ:ALIM) was the target of a large growth in short interest in the month of June. As of June 30th, there was short interest totalling 229,300 shares, a growth of 142.1% from the June 15th total of 94,700 shares. Based on an average daily trading volume, of 312,200 shares, the short-interest ratio is presently 0.7 days.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Stonepine Capital Management LLC increased its stake in Alimera Sciences by 0.4% during the 4th quarter. Stonepine Capital Management LLC now owns 3,999,459 shares of the biopharmaceutical company’s stock valued at $17,278,000 after purchasing an additional 15,773 shares in the last quarter. Fifth Lane Capital LP bought a new stake in Alimera Sciences during the 1st quarter valued at about $83,000. Hillsdale Investment Management Inc. bought a new stake in Alimera Sciences during the 1st quarter valued at about $169,000. Ancora Advisors LLC bought a new stake in Alimera Sciences during the 1st quarter valued at about $915,000. Finally, Vanguard Group Inc. increased its stake in Alimera Sciences by 61.1% during the 1st quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock valued at $4,077,000 after purchasing an additional 396,506 shares in the last quarter. 99.83% of the stock is currently owned by institutional investors.

Alimera Sciences Stock Up 0.7 %

Shares of Alimera Sciences stock opened at $5.60 on Friday. The company has a debt-to-equity ratio of 1.71, a current ratio of 2.62 and a quick ratio of 2.51. The company has a 50-day moving average of $3.88 and a 200 day moving average of $3.81. The firm has a market cap of $293.38 million, a price-to-earnings ratio of -3.57 and a beta of 1.28. Alimera Sciences has a 1 year low of $2.61 and a 1 year high of $5.65.

Alimera Sciences (NASDAQ:ALIM) last issued its quarterly earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.08). The business had revenue of $23.01 million during the quarter, compared to the consensus estimate of $23.72 million. Alimera Sciences had a negative return on equity of 53.49% and a negative net margin of 23.74%. During the same quarter in the previous year, the business earned ($0.71) earnings per share. As a group, sell-side analysts anticipate that Alimera Sciences will post -0.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on ALIM shares. Maxim Group reissued a “hold” rating on shares of Alimera Sciences in a research report on Tuesday, June 25th. Alliance Global Partners restated a “neutral” rating on shares of Alimera Sciences in a report on Tuesday, June 25th. StockNews.com began coverage on shares of Alimera Sciences in a report on Friday. They issued a “hold” rating for the company. Finally, HC Wainwright lowered shares of Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 price objective for the company. in a report on Tuesday, June 25th.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).